poisar

Stocks · News reference

Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.

BenzingaBenzinga News-desk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaVandana Singh

    Why Is BioNTech Stock Gaining Monday?

    BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.

  2. The Motley FoolEric Volkman

    Why Pfizer Stock Was so Healthy in August

    Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.